Published in J Am Chem Soc on March 04, 2015
Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun (2017) 0.75
The stereodivergent formation of 2,6-cis and 2,6-trans-tetrahydropyrans: experimental and computational investigation of the mechanism of a thioester oxy-Michael cyclization. Chem Sci (2016) 0.75
The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature (1984) 28.58
Structural basis of protein kinase C isoform function. Physiol Rev (2008) 4.00
Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell (1995) 3.08
Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem (1977) 3.02
Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab (2009) 2.81
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 2.76
The chemistry and biology of the bryostatin antitumour macrolides. Nat Prod Rep (2002) 2.38
Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov (2012) 2.33
Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol (2014) 2.32
Crystal structure and allosteric activation of protein kinase C βII. Cell (2011) 2.19
Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature (2008) 2.11
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
The practical synthesis of a novel and highly potent analogue of bryostatin. J Am Chem Soc (2002) 1.94
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J Am Chem Soc (2008) 1.76
Immunologic strategies for HIV-1 remission and eradication. Science (2014) 1.70
A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J Biol Chem (2006) 1.69
Novel "nonkinase" phorbol ester receptors: the C1 domain connection. Mol Pharmacol (2002) 1.66
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Intramolecular conformational changes optimize protein kinase C signaling. Chem Biol (2014) 1.58
A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci U S A (2007) 1.55
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci U S A (1988) 1.49
Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest (2003) 1.49
Enantioselective formal total synthesis of the antitumor macrolide bryostatin 7. Org Lett (2006) 1.42
Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci U S A (2008) 1.42
Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs. Proc Natl Acad Sci U S A (1986) 1.39
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34
Residues in the second cysteine-rich region of protein kinase C delta relevant to phorbol ester binding as revealed by site-directed mutagenesis. J Biol Chem (1995) 1.33
NMR structure of a protein kinase C-gamma phorbol-binding domain and study of protein-lipid micelle interactions. Biochemistry (1997) 1.28
Protein kinase C pharmacology: refining the toolbox. Biochem J (2013) 1.27
The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc Natl Acad Sci U S A (1998) 1.25
Solution structure of a cysteine rich domain of rat protein kinase C. Nat Struct Biol (1994) 1.25
Total synthesis of bryostatin 1. J Am Chem Soc (2010) 1.25
New approaches to the total synthesis of the bryostatin antitumor macrolides. Chem Asian J (2010) 1.24
Total synthesis of bryostatin 7 via C-C bond-forming hydrogenation. J Am Chem Soc (2011) 1.19
Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci U S A (2011) 1.18
A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis (2009) 1.16
The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity. Org Lett (2008) 1.15
Total synthesis of bryostatin 9. J Am Chem Soc (2011) 1.11
Utilization of an oxonia-Cope rearrangement as a mechanistic probe for Prins cyclizations. J Am Chem Soc (2005) 1.10
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol (2009) 1.09
Molecular modeling, total synthesis, and biological evaluations of C9-deoxy bryostatin 1. Angew Chem Int Ed Engl (2010) 1.06
Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke (2013) 1.05
Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Curr Drug Discov Technol (2004) 1.02
Postischemic PKC activation rescues retrograde and anterograde long-term memory. Proc Natl Acad Sci U S A (2009) 0.99
Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. Pharmacol Ther (2010) 0.96
Solution structure of cysteine-rich domain of protein kinase C alpha. J Biochem (1995) 0.95
"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget (2012) 0.95
Probing the determinants of diacylglycerol binding affinity in the C1B domain of protein kinase Cα. J Mol Biol (2011) 0.88
Single-molecule studies reveal a hidden key step in the activation mechanism of membrane-bound protein kinase C-α. Biochemistry (2014) 0.88
C1 domains: structure and ligand-binding properties. Chem Rev (2014) 0.88
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
Identification, activity, and structural studies of peptides incorporating the phorbol ester-binding domain of protein kinase C. Proc Natl Acad Sci U S A (1995) 0.87
PKC activator therapeutic for mild traumatic brain injury in mice. Neurobiol Dis (2010) 0.87
Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core. J Am Chem Soc (2014) 0.85
Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties. J Am Chem Soc (2014) 0.85
Happy birthday protein kinase C: past, present and future of a superfamily. Pharmacol Res (2007) 0.83
Bryostatin-1 promotes long-term potentiation via activation of PKCα and PKCε in the hippocampus. Neuroscience (2012) 0.83
Current status and future prospects of C1 domain ligands as drug candidates. Curr Top Med Chem (2011) 0.83
Charge density influences C1 domain ligand affinity and membrane interactions. Chembiochem (2014) 0.82
Identification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase Cθ (PKCθ). Biochem J (2013) 0.82
Using solid-state 31P{19F} REDOR NMR to measure distances between a trifluoromethyl group and a phosphodiester in nucleic acids. J Magn Reson (2005) 0.81
Lead Diversification through a Prins-Driven Macrocyclization Strategy: Application to C13-Diversified Bryostatin Analogues. Synthesis (Stuttg) (2013) 0.81
Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase Cδ*. Biophys J (2012) 0.81
REDOR NMR for drug discovery. Bioorg Med Chem Lett (2013) 0.80
Interactions of protein kinase C-α C1A and C1B domains with membranes: a combined computational and experimental study. J Am Chem Soc (2014) 0.80
Application of REDOR NMR in natural product chemistry. Chem Commun (Camb) (2009) 0.78
Interfacial partitioning of a loop hinge residue contributes to diacylglycerol affinity of conserved region 1 domains. J Biol Chem (2014) 0.78
1H, 13C and 15N NMR assignments of the C1A and C1B subdomains of PKC-delta. Biomol NMR Assign (2010) 0.77
Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin. Chem Rec (2014) 0.77
Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain. J Biomol Struct Dyn (2014) 0.76
Yasutomi Nishizuka: father of protein kinase C. J Biochem (2010) 0.76